need
effect
treatment
cure
patient
decreas
viru
carriag
durat
method
conduct
uncontrol
noncompar
observ
studi
cohort
rel
mildli
infect
inpati
treat
combin
hydroxychloroquin
azithromycin
period
least
three
day
three
main
measur
clinic
outcom
contagi
assess
pcr
cultur
length
stay
infecti
diseas
unit
idu
result
patient
improv
clinic
except
one
yearold
patient
die
one
yearold
patient
still
intens
care
rapid
fall
nasopharyng
viral
load
note
neg
viru
cultur
patient
respiratori
sampl
neg
patient
consequ
patient
abl
rapidli
discharg
idu
mean
length
stay
five
day
conclus
believ
urgenc
evalu
effect
potentiallylif
save
therapeut
strategi
larger
scale
treat
cure
patient
earli
stage
irrevers
sever
respiratori
complic
take
hold
decreas
durat
carriag
avoid
spread
diseas
furthermor
cost
treatment
neglig
patient
age
year
age
year
howev
highli
like
larg
number
asymptomat
carrier
popul
thu
probabl
mortal
rate
overestim
take
exampl
outbreak
onboard
diamond
princess
cruiseship
fatal
rate
franc
face
onslaught
case
march
thu
critic
urgent
need
effect
treatment
order
cure
symptomat
patient
also
decreas
durat
viru
carriag
thu
limit
transmiss
commun
among
candid
drug
treat
reposit
old
drug
use
antivir
treatment
compel
strategi
knowledg
drug
safeti
profil
side
effect
pharmacokinet
drug
interact
alreadi
well
known
accord
onlin
survey
conduct
end
march
intern
panel
physician
report
person
prescrib
see
colleagu
prescrib
hydroxychloroquin
chloroquin
report
azithromycin
similar
antibiot
fight
addit
treat
patient
believ
hydroxychloroquin
chloroquin
effect
therapi
diseas
believ
azithromycin
similar
antibiot
given
one
third
physician
prescrib
drug
patient
critic
import
evalu
effect
medic
http
publiccdnsermo
three
studi
demonstr
chloroquin
phosphat
inhibit
two
demonstr
hydroxychloroquin
sulfat
inhibit
vitro
addit
parallel
studi
evalu
vitro
combin
hydroxychloroquin
azithromycin
infect
cell
show
consider
synergi
two
product
use
dose
mimic
concentr
like
obtain
human
http
studi
point
drug
repurpos
may
identifi
approv
drug
could
use
treatment
diseas
includ
notabl
chloroquin
hydroxychloroquin
azithromycin
well
antidiabet
metformin
angiotensin
receptor
inhibitor
sartan
statin
simvastatin
addit
chloroquin
demonstr
efficaci
chines
patient
clinic
trial
reduc
fever
improv
ct
imag
delay
diseas
progress
lead
chines
expert
recommend
chloroquinebas
treatment
mg
twice
per
day
ten
day
first
linetreat
mild
moder
sever
case
preliminari
clinic
trial
small
cohort
patient
demonstr
treat
hydroxychloroquin
mg
per
day
n
patient
signific
reduct
viral
carriag
inclus
patient
test
neg
viru
nasopharyng
pcr
compar
untreat
control
n
patient
test
neg
use
pcr
inclus
addit
twenti
patient
treat
hydroxychloroquin
six
receiv
azithromycin
five
day
purpos
prevent
bacteri
superinfect
virolog
cure
inclus
compar
remain
patient
contrast
chines
studi
conduct
patient
show
signific
differ
patient
treat
mg
per
day
five
day
n
control
n
regard
pharyng
carriag
viral
rna
howev
patient
receiv
multipl
addit
treatment
includ
antivir
final
anoth
chines
studi
conduct
patient
show
significantli
shorten
bodi
temperatur
recoveri
time
cough
remiss
time
larger
proport
improv
pneumonia
assess
ct
scan
patient
treat
mg
per
day
five
day
n
control
n
recent
chines
survey
reveal
median
durat
viral
shed
day
iqr
survivor
detect
death
nonsurvivor
shortest
observ
durat
viral
shed
among
survivor
eight
day
wherea
longest
day
therefor
treatment
enabl
viral
carriag
clear
covidpati
clinic
cure
earli
stage
diseas
would
help
limit
transmiss
viru
report
describ
result
uncontrol
noncompar
observ
studi
cohort
rel
mildli
infect
patient
treat
hydroxychloroquin
combin
azithromycin
period
least
three
day
three
main
endpoint
clinic
outcom
ii
contagi
assess
pcr
cultur
iii
length
stay
infecti
diseas
id
unit
studi
conduct
univers
hospit
institut
infect
marseil
franc
patient
pcrdocument
rna
nasopharyng
sampl
admit
infecti
diseas
id
ward
note
six
patient
hydroxychloroquin
azithromycin
combin
enrol
institut
describ
first
paper
sixday
followup
n
also
includ
present
studi
longer
followup
upon
admiss
patient
group
two
categori
upper
respiratori
tract
infect
urti
present
rhiniti
andor
pharyng
andor
isol
lowgrad
fever
myalgia
ii
lower
respiratori
tract
infect
lrti
present
symptom
pneumonia
bronchiti
time
onset
symptom
admiss
time
onset
symptom
treatment
document
risk
factor
sever
includ
older
age
cancer
cardiovascular
diseas
hypertens
diabet
well
chronic
obstruct
pulmonari
diseas
obes
immunosuppress
treatment
document
nation
earli
warn
score
news
patient
collect
upon
ward
admiss
follow
news
score
calcul
base
follow
paramet
age
respiratori
rate
oxygen
satur
temperatur
systol
blood
pressur
puls
rate
level
conscious
defin
three
risk
categori
clinic
deterior
low
score
news
medium
score
news
high
score
covid
patient
need
oxygen
therapi
transfer
intens
care
unit
icu
death
length
stay
id
ward
document
patient
systemat
underw
unenhanc
chest
lowdos
comput
tomographi
ldct
upon
admiss
soon
use
singl
ct
machin
revolut
evo
ge
healthcar
wi
usa
imag
analys
experienc
chest
radiologist
classifi
compat
compat
pneumonia
imag
consid
compat
presenc
peripher
multifoc
groundglass
opac
without
reticul
presenc
alveolar
consolid
crazi
pave
pattern
nasopharyng
swab
collect
daili
basi
discharg
except
discharg
patient
also
sampl
followup
outpati
depart
possibl
rna
assess
realtim
revers
transcriptionpcr
use
hydrolysi
probebas
system
target
gene
encod
envelop
e
protein
previous
describ
neg
result
viral
rna
detect
defin
cycl
threshold
ct
valu
cultur
attempt
select
conveni
sampl
patient
aliquot
liquid
collect
nasopharyng
swab
pass
pore
size
centrifug
filter
merck
millipor
darmstadt
germani
inocul
well
cultur
micropl
four
well
contain
vero
cell
atcc
minimum
essenti
medium
cultur
medium
foetal
calf
serum
glutamin
centrifug
g
micropl
incub
plate
observ
everi
day
evid
cytopathogen
effect
presumpt
detect
viru
supernat
perform
use
sem
hitachi
scan
electron
microscop
confirm
specif
rtpcr
patient
contraind
supplementari
document
offer
combin
mg
oral
hydroxychloroquin
sulfat
three
time
per
day
ten
day
combin
azithromycin
mg
follow
mg
per
day
next
four
day
patient
pneumonia
news
broad
spectrum
antibiot
ceftriaxon
ad
hydroxychloroquin
azithromycin
twelvelead
electrocardiogram
ecg
perform
patient
treatment
two
day
treatment
began
ecg
review
senior
cardiologist
treatment
either
start
discontinu
qtc
bazett
formula
ms
risk
benefit
ratio
hydroxychloroquin
azithromycin
estim
infectologist
agre
cardiologist
qtc
ms
risk
benefit
ratio
hydroxychloroquin
azithromycin
combin
estim
infectologist
agre
cardiologist
qtc
ms
treatment
start
ecg
show
pattern
suggest
channelopathi
ie
lonq
qt
pattern
brugada
pattern
malign
earli
repolaris
pattern
riskbenefit
ratio
discuss
show
signific
abnorm
ie
patholog
q
wave
left
ventricular
hypertrophi
left
bundl
branch
block
addit
drug
potenti
prolong
qt
interv
discontinu
treatment
symptomat
treatment
includ
oxygen
ad
need
ionogram
verif
serum
potassium
level
particular
systemat
perform
upon
admiss
need
standard
blood
chemistri
check
criteria
discharg
chang
cours
studi
initi
patient
two
success
neg
nasopharyng
sampl
result
pcr
assay
ct
valu
discharg
march
patient
singl
nasopharyng
sampl
pcr
ct
valu
discharg
home
transfer
unit
continu
treatment
ultim
crucial
need
admit
new
untreat
inpati
inpati
alreadi
receiv
treatment
pcr
ct
valu
good
clinic
outcom
good
adher
treatment
also
discharg
possibl
followup
continu
unit
outpati
consult
patient
pcr
ct
valu
consid
presum
contagi
base
result
studi
show
cultur
posit
condit
http
patient
posit
cultur
consid
contagi
primari
endpoint
aggress
clinic
cours
requir
oxygen
therapi
transfer
icu
least
three
day
treatment
ii
contagi
assess
pcr
cultur
iii
length
stay
id
ward
variat
cultur
posit
rate
assess
statist
proport
varianc
explain
ct
valu
consid
adequ
fit
coeffici
determin
statist
protocol
approv
ethic
committe
univers
hospit
institut
infect
studi
perform
accord
good
clinic
practic
recommend
declar
helsinki
amend
retrospect
studi
cohort
patient
receiv
standard
treatment
follow
research
protocol
previous
regist
sinc
use
hydroxychloroquin
author
french
govern
treat
covid
patient
fda
approv
usa
addit
antibiot
azithromycin
regularli
use
treat
respiratori
infect
also
includ
standard
therapeut
manag
patient
patient
inform
treatment
receiv
formal
consent
sign
institut
patient
allow
us
perform
anonym
observ
retrospect
studi
context
standard
therapeut
manag
patient
total
patient
confirm
hospitalis
infect
univers
hospit
institut
n
temporari
unit
n
date
entri
march
patient
receiv
treatment
hydroxychloroquin
azithromycin
least
three
day
followedup
least
six
day
includ
analysi
median
age
patient
year
rang
year
mf
sex
ratio
patient
least
one
chronic
condit
known
risk
factor
sever
form
hypertens
diabet
chronic
respiratori
diseas
frequent
time
onset
symptom
hospitalis
averag
five
day
longest
time
day
patient
present
lrti
symptom
urti
symptom
patient
febril
four
patient
asymptomat
carrier
major
patient
low
news
score
patient
ldct
compat
pneumonia
mean
pcr
ct
valu
travel
medicin
infecti
diseas
xxx
xxxx
xxxx
mean
time
onset
symptom
initi
treatment
day
patient
treat
day
admiss
day
total
patient
receiv
treatment
daili
basi
throughout
whole
studi
period
last
maximum
ten
day
one
patient
treatment
stop
day
although
well
toler
potenti
risk
interact
anoth
drug
advers
event
rare
minor
major
patient
favour
outcom
discharg
unit
time
write
low
news
score
requir
oxygen
therapi
stay
id
ward
three
patient
transfer
icu
two
improv
return
id
ward
one
yearold
patient
still
icu
time
write
final
one
yearold
patient
transfer
icu
die
id
ward
supplementari
tabl
rapid
fall
nasopharyng
viral
load
test
qpcr
note
neg
number
patient
presum
contagi
pcr
ct
valu
steadili
decreas
overtim
reach
zero
day
fig
mark
decreas
observ
six
day
treatment
ten
day
two
patient
still
presum
contagi
ct
valu
respect
proport
patient
ct
valu
significantli
decreas
overtim
r
viru
cultur
patient
respiratori
sampl
neg
patient
number
contagi
patient
posit
cultur
earli
decreas
three
day
treatment
fig
five
day
treatment
two
patient
contagi
posttreat
one
two
patient
contagi
ceas
contagi
day
proport
neg
cultur
significantli
decreas
overtim
r
patient
discharg
id
ward
studi
period
mean
time
initi
discharg
day
mean
length
stay
day
pose
two
major
challeng
physician
first
therapeut
manag
patient
context
necessari
avoid
worsen
evolut
usual
occur
around
tenth
day
may
result
acut
respiratori
distress
syndrom
prognosi
particular
elderli
poor
whatev
caus
therefor
primari
therapeut
object
treat
peopl
moder
sever
infect
earli
enough
stage
avoid
progress
seriou
irrevers
condit
administ
hydroxychloroquin
combin
azithromycin
abl
observ
improv
case
except
one
patient
arriv
advanc
form
age
evolut
irrevers
patient
cohort
peopl
combin
hydroxychloroquin
azithromycin
result
clinic
improv
appear
superior
compar
outcom
hospitalis
patient
describ
literatur
cohort
chines
inpati
receiv
antibiot
receiv
combin
lopinavir
ritonavir
median
durat
fever
day
cough
day
survivor
casefat
rate
favour
evolut
patient
hydroxychloroquin
azithromycin
parallel
rel
rapid
decreas
viral
rna
load
assess
pcr
even
rapid
assess
cultur
data
import
compar
literatur
show
viral
rna
load
remain
high
three
week
patient
absenc
specif
treatment
extrem
case
last
month
studi
conduct
chines
inpati
show
high
viral
rna
load
associ
sever
diseas
furthermor
studi
conduct
small
group
chines
inpati
viral
rna
posit
detect
resolut
symptom
median
durat
day
maximum
eight
day
therefor
rapid
decreas
viral
rna
load
one
element
suggest
effect
treatment
furthermor
knowledg
measur
viral
cultur
treatment
also
evalu
first
time
fall
cultur
posit
second
day
remark
although
rel
small
number
case
peopl
maintain
posit
cultur
second
challeng
rapid
spread
diseas
popul
contagi
individu
elimin
viral
carriag
human
reservoir
viru
recent
recognis
prioriti
end
rapid
deceas
posit
cultur
patient
respiratori
sampl
treatment
hydroxychloroquin
plu
azithromycin
support
effect
combin
thu
addit
direct
therapeut
role
combin
play
role
control
diseas
epidem
limit
durat
viru
shed
last
sever
week
absenc
specif
treatment
institut
contain
individu
room
treat
highli
contagi
patient
current
turnov
rate
per
day
allow
us
receiv
larg
number
contagi
patient
earli
discharg
chloroquin
hydroxychloroquin
extrem
wellknown
drug
alreadi
prescrib
billion
peopl
anecdot
report
heart
complic
drug
patient
underli
condit
would
use
perform
ecg
begin
treatment
problem
solv
hospitalis
patient
risk
continu
care
unit
ecg
monitor
allow
earli
detect
treatment
possibl
cardiac
sideeffect
azithromycin
drug
wide
prescrib
respiratori
infect
recent
studi
show
one
eight
american
patient
prescrib
azithromycin
inde
probabl
billion
azithromycin
prescript
around
world
sinc
first
discov
toxic
two
drug
therefor
pose
major
problem
possibl
toxic
combin
suggest
anecdot
report
knowledg
never
demonstr
work
limit
descript
pilot
studi
conduct
patient
rel
mild
clinic
present
attempt
analyt
approach
account
possibl
confound
includ
notabl
sever
ill
approach
current
plan
larger
set
patient
treatment
institut
conclus
provid
evid
benefici
effect
coadministr
hydroxychloroquin
azithromycin
treatment
potenti
effect
earli
reduct
contagi
given
urgent
therapeut
need
manag
diseas
effect
safe
drug
neglig
cost
hydroxychloroquin
azithromycin
believ
urgent
need
evalu
strategi
treat
cure
patient
earli
stage
irrevers
sever
respiratori
complic
take
hold
decreas
durat
carriag
avoid
spread
diseas
studi
support
institut
hospitalouniversitair
ihu
infect
nation
research
agenc
program
investiss
davenir
refer
provenc
alp
dazur
european
fund
feder
primi
